Acura Pharmaceuticals, Inc.  

(Public, NASDAQ:ACUR)   Watch this stock  
Find more results for ACUR
-0.02 (-0.84%)
Nov 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.32 - 2.40
52 week 2.05 - 6.75
Open 2.33
Vol / Avg. 30,182.00/10,459.00
Mkt cap 27.97M
P/E     -
Div/yield     -
EPS -0.65
Shares 11.80M
Beta 1.83
Inst. own 60%
Nov 5, 2015
Q3 2015 Acura Pharmaceuticals Inc Earnings Call
Nov 4, 2015
Q3 2015 Acura Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -1261.43% -1758.86%
Operating margin -1145.24% -1624.37%
EBITD margin - -1561.12%
Return on average assets -62.68% -59.15%
Return on average equity -164.54% -114.99%
Employees 15 -
CDP Score - -


Suite 120, 616 N. North Court
United States - Map
+1-847-7057709 (Phone)
+1-847-7055399 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Acura Pharmaceuticals, Inc. is a pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three proprietary platform technologies, which can be used to develop multiple products. The Company's Aversion Technology is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules intended to address some common methods of product tampering associated with opioid abuse. The Company has also developed Impede Technology, which is a combination of inactive ingredients that prevent the extraction of pseudoephedrine from tablets and disrupt the direct conversion of pseudoephedrine from tablets into methamphetamine. The Company's third abuse deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested.

Officers and directors

Robert B. Jones President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Peter A. Clemens Chief Financial Officer, Senior Vice President, Secretary
Age: 62
Bio & Compensation  - Reuters
Robert A. Seiser CPA Vice President, Corporate Controller and Treasurer
Age: 51
Bio & Compensation  - Reuters
J. Bradley Rivet Vice President - Marketing
Age: 61
Bio & Compensation  - Reuters
Albert W. Brzeczko Ph.D. Vice President -Technical Affairs
Age: 58
Bio & Compensation  - Reuters
James F. Emigh Vice President - Corporate Development
Age: 59
Bio & Compensation  - Reuters
George K. Ross Independent Director
Age: 73
Bio & Compensation  - Reuters
William G. Skelly Independent Director
Age: 64
Bio & Compensation  - Reuters
Immanuel Thangaraj Independent Director
Age: 44
Bio & Compensation  - Reuters
Bruce F. Wesson Independent Director
Age: 72
Bio & Compensation  - Reuters